Comunicación
Nº 043
Comunicación |
|
MF Fresno, MJ Pérez del Rio, B. Madrigal, M Veiga, JM Diaz Iglesias(*) y A Herrero
|
|
1.- Kerr JFR, Wyllie AH and Currie AR: Apoptosis: A basic biologic phenomenon with widwe-ranging implication in tissue kinetics. Br J Cancer 1972,26:239-257
2.- Majno G and Joris I: Apoptosis and necrosis. An overview of cell death. Am J Pathol 1995, 146:3- 15.
3.- Carson DA, Ribeiro JM. Apoptosis and disease. Lancet 1993; 341: 1251-1254.
4.- Korsmeyer SJ. Bcl-2 iniciates a new category of oncogenes: regulators of cell death. Blood 1992; 80: 879-886.
5.- Krajewski13.- Krajewski S, Krajewska M, Shabaik A, Miyashita T, Wang HG, Reed JC. Immunohistochemical determination of in vivo distribution of Bax, a dominant inhibitor of Bcl-2. Am J Pathol 1994; 145: 1323-1336.
6.- Salomon RN, Díaz-Cano S. Introduction to apoptosis. Diagn Mol Pathol 1995; 4: 235-238.
7.- Shibata D, Hu E, Weiss LM, Brynes RK, Nathwani BN. Detection of specific t(14;18) chromosomal translocation in fixed tissues. Hum Pathol 1990; 21: 199-203.
8.- Lu QL, Abel P, Foster CS, Lalani E. bcl-2: role in epithelial differentiation and oncogenesis. Hum Pathol 1996; 27: 102-110
9.-Siziopikou KP, Prioleau JE, Harris JR, Schnitt SJ: Bcl-2 expression in the expectrum of prinvasive breast lesions. Cancer 1996;77:499-506
10.-Bargou RC, Daniel PT, Mapara MY, Bommert K, Wagener C, Kallinich B, Royer HD, Dorken B. Expression of the bcl-2 gene family in normal and malignant breast tissue: low bax-alpha expression in tumor cells correlates with resistance towards apoptosis. Int J Cancer 1995; 60: 854-859.
11.- Alsabeh R, Wilson CS, Anh CW, Vasef MA, Battifora H. Expression of bcl-2 by breast cancer: a possible diagnostic appication. Mod Pathol 1996; 9: 439-444.
12.- Joensuu H, Pylkkänen L, Toikkanen S. Bcl-2 protein expression and long-term survival in breast cancer. Am J Pathol 1994; 145: 1191-1198.
13.- Cecarelli C, Santini D, Chieco P, Taffurelli M, Marrano D, Mancini AM. Multiple expression patterns of biopathological markers in primary invasive breast carcinoma. A useful tool for elucidating its biological behaviour. Ann Oncol 1995; 6: 275-282.
14.- Lipponen P, Pietilainen T, Kosma VM, Aaltomas S, Eskelinen M, Syrjanen K. Apoptosis suppresing protein bcl-2 is expressed in well-differentiated breast carcinomas with favourable prognosis. J Pathol 1995; 177: 49-55.
15.- Dogliani C, Dei Tos AP, Laurino L et al. The prevalence of bcl-2 immunoreactivity in breast carcinomas and its cliniocopathological correlates, with particualar reference to estrogen receptor status. Virchows Archiv 1994, 424:47-51.
16.- Bhargava V, Kell DL, Van de Rijn M, Warnke RA. Bcl-2 immunoreactivity in breast carcinoma correlates with hormone receptor positivity. Am J Pathol 1994; 145: 535-540.
17.- Silvestrini R, Benini E, Veneroni S, Daidone MG, Tomasic G, Squiccirini P, Salvadori B. p53 and Bcl-2 expression correlates with clinical outcome in a series on node-positive breast cancer patients. J Cli Oncol 1996; 14: 1604-1610.
18.- R, Veneroni S, Daidone MG et al. : The bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node negative negative breast cancer patients. J Natl Cancer Inst 1994, 86:499-504
19.- Gorczyca W, Markiewski M, Kram A, Tuzi T, Domagala W. Immunohistochemical analysis of bcl- 2 and p53 expression in breast carcinomas: their correlation with Ki-67 growth fraction. Virchows Arch 1995; 426: 229-233.
20.- Hurlimann J, Larrinaga B, Vala DL. bcl-2 protein in invasive ductal breast carcinomas. Virchows Arch 1995; 426: 163-168.
21.- Gee JM, Robertson JF, Ellis IO, Wilsher P, McClelland RA, Hoyle HB, Kyme Sr, Finlay P, Blame RW, Nicholson RI. Immunocytochemical localization of bcl-2 protein in human breast cancers and its relatioship to a series of prognostic markers and response to endocrine therapy. Int J Cancer 1994; 59: 619- 628.
22.-Hellemans P, Van Dam PA, Weyler J, Van Oosterom AT, Buytaert P, Van Marck E. Prognostic value of Bcl-2 expression in invasive breast cancer. Br J Cancer 1995;72:354-360
23.-Sierra A, Lloveras B, Castellsague X, Moreno L, Garcia Ramirez M, Fabra A. Bcl-2 expression is associated with lymph node metastasis in human ductal breast carcinoma. Int J Cancer 1995;60:54-60
24.- Candi E, Melino G, De Laurenzi V, Piacentini P, Guerrieri A, Spinedi A, Knight A. Tamoxifen and somatostatin affect tumours by inducing apoptosis. Cancer Lett 1995; 96: 141-145.
25.-Kapranos N, Karaiosifidi H, Valavanis C, Kouri E, Vasilaros S .Prognostic significance of apoptosis related proteins Bcl-2 and Bax in node-negative breast cancer patients. Anticancer Res, 1997; 17:4A, 2499-505
26.- Binder C, Marx D, Binder L, Schauer A, Hiddemann W. Expression of Bax in relation to Bcl-2 and other predictive parameters in breast cancer. Ann Oncol, 1996 Feb, 7:2, 129-33
27.-Veronese S, Mauri FA, Caffo O, Scaioli M, Aldovini D, Perrone G, Galligioni E, Doglioni C, Dalla Palma P, Barbareschi M. Bax immunohistochemical expression in breast carcinoma: a study with long term follow-up. Int J Cancer, 1998; 79:13-8
28.-Kapucuoglu N, Losi L, Eusebi V . Immunohistochemical localization of Bcl-2 and Bax proteins in in situ and invasive duct breast carcinomas. Virchows Arch, 1997 ; 430:17-22
29.- Krajewski S, Blomqvist C, Franssila K, Krajewska M, Wasenius VM, Niskanen E, Nordling S, Reed JC. Reduced expression of the proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and sorther survival in women with metastatic breast adenocarcinoma. Cancer Res 1995; 55:4471-4478.
|
|
